PepTivator
®
SARS-CoV-2 Prot_S Complete is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the complete protein coding sequence (aa 5–1273) of the surface or spike glycoprotein ("S") of SARS Coronavirus 2 (GenBank MN908947.3, Protein QHD43416.1).
The PepTivator is available in two different quality grades. The research-grade product has an average purity of 70%, whereas peptides of the premium-grade product are individually purified via HPLC having each a purity of >90%.
In contrast, other PepTivators covering the SARS-CoV-2 spike glycoprotein ("S") are available only in research grade quality. PepTivator SARS-CoV-2 Prot_S covers

Data and images for
PepTivator
®
SARS-CoV-2 Prot_S Complete

Figures

Figure 1

View details
Schematic alignment of the spike glycoprotein and different SARS‑CoV‑2 PepTivator Peptide Pools based on this protein.
PepTivator SARS‑CoV‑2 Prot_S covers the predicted immunodominant domains of the SARS‑CoV‑2 spike glycoprotein (protein S), PepTivator SARS‑CoV‑2 Prot_S1 covers the N-terminal S1 domain, PepTivator SARS‑CoV‑2 Prot_S+ covers a part of the C-terminal S2 domain, and PepTivator SARS-CoV-2 Prot_S Complete covers the whole protein sequence of the spike protein without the first 4 amino acids of the signal peptide.

Figure 1

Schematic alignment of the spike glycoprotein and different SARS‑CoV‑2 PepTivator Peptide Pools based on this protein.
PepTivator SARS‑CoV‑2 Prot_S covers the predicted immunodominant domains of the SARS‑CoV‑2 spike glycoprotein (protein S), PepTivator SARS‑CoV‑2 Prot_S1 covers the N-terminal S1 domain, PepTivator SARS‑CoV‑2 Prot_S+ covers a part of the C-terminal S2 domain, and PepTivator SARS-CoV-2 Prot_S Complete covers the whole protein sequence of the spike protein without the first 4 amino acids of the signal peptide.

Figure 2

View details
Quantitative analysis of spike protein–specific CD4+ T cells in convalescent COVID-19 donors.
Quantitative analysis of SARS‑CoV‑2–specific CD4
+
T cells of convalescent COVID-19 donors highlights that similar numbers of activated T cells can be observed whether the mix of three PepTivator Peptide Pools
(PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or the single PepTivator SARS-CoV-2 Prot_S Complete is used.

Figure 2

Quantitative analysis of spike protein–specific CD4+ T cells in convalescent COVID-19 donors.
Quantitative analysis of SARS‑CoV‑2–specific CD4
+
T cells of convalescent COVID-19 donors highlights that similar numbers of activated T cells can be observed whether the mix of three PepTivator Peptide Pools
(PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or the single PepTivator SARS-CoV-2 Prot_S Complete is used.

Figure 3

View details
Stimulation with SARS-CoV-2 PepTivator Peptide Pools reveals the presence of virus-specific CD4+ T cells after vaccination.
A whole blood sample of a vaccinated donor was stimulated with the mix of three PepTivator Peptide Pools (PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or with PepTivator SARS-CoV-2 Prot_S Complete alone.
Both, the applied mix of peptide pools as well as SARS-CoV-2 Prot_S Complete cover the complete sequence of the spike protein. As negative control, the sample was left unstimulated. T cell lineage surface markers and intracellular cytokines were stained, and cells were analyzed using a MACSQuant Analyzer 16. The presented plots are exemplary data showing CD154 and TNF-α for pregated CD4
+
T cells.

Figure 3

Stimulation with SARS-CoV-2 PepTivator Peptide Pools reveals the presence of virus-specific CD4+ T cells after vaccination.
A whole blood sample of a vaccinated donor was stimulated with the mix of three PepTivator Peptide Pools (PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or with PepTivator SARS-CoV-2 Prot_S Complete alone.
Both, the applied mix of peptide pools as well as SARS-CoV-2 Prot_S Complete cover the complete sequence of the spike protein. As negative control, the sample was left unstimulated. T cell lineage surface markers and intracellular cytokines were stained, and cells were analyzed using a MACSQuant Analyzer 16. The presented plots are exemplary data showing CD154 and TNF-α for pregated CD4
+
T cells.

Specifications for
PepTivator
®
SARS-CoV-2 Prot_S Complete

Overview

PepTivator
®
SARS-CoV-2 Prot_S Complete is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the complete protein coding sequence (aa 5–1273) of the surface or spike glycoprotein ("S") of SARS Coronavirus 2 (GenBank MN908947.3, Protein QHD43416.1).
The PepTivator is available in two different quality grades. The research-grade product has an average purity of 70%, whereas peptides of the premium-grade product are individually purified via HPLC having each a purity of >90%.
In contrast, other PepTivators covering the SARS-CoV-2 spike glycoprotein ("S") are available only in research grade quality. PepTivator SARS-CoV-2 Prot_S covers selected immunodominant sequence domains of the spike protein (aa 304–338, 421–475, 492–519, 683–707, 741–770, 785–802, and 885–1273), Prot_S1 the complete N-terminal S1 domain (aa 1–692) and Prot_S+ parts of the C-terminal S2 domain (aa 689–895).
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as novel coronavirus 2019-nCoV, causes fever, severe respiratory illness and can lead to life threatening pneumonia. The first cases of this disease, termed COVID-19 for coronavirus disease 2019, have been detected in December 2019 in Wuhan, China. SARS-CoV-2 Prot_S stands for the surface glycoprotein of SARS-CoV-2, the "spike protein".
This protein is responsible for the recognition and binding of the coronavirus to the host cell. Once SARS-CoV-2 has bound to the ACE2 receptor of the host cell, fusion of viral envelope and host cell membrane starts, which enables the viral genome to enter the host cell. Thus, the spike protein is crucial for the infection of cells with coronaviruses and has been used as a target for vaccine development.
The spike protein consists of two functional domains: The S1 domain contains the receptor binding domain to the ACE2 receptor and the S2 subunit mediates membrane fusion. Cleavage at the S1/S2 boundary (aa-residues 685 and 686) via cellular proteases is crucial to prime the protein for the entry to the host cell. The cleavage site distinguishes SARS-CoV-2 from SARS-CoV spike protein sequence, and is thought to be an important feature not only for its zoonotic potential, but also for increased SARS-CoV-2 transmissibility.
The PepTivator SARS-CoV-2 Prot_S Complete covers the whole protein coding sequence of the surface or spike glycoprotein ("S") without the first four amino acids of the signal peptide. In contrast, PepTivator SARS-CoV-2 Prot_S covers selected immunodominant sequence domains of the spike protein (aa 304–338, 421–475, 492–519, 683–707, 741–770, 785–802, and 885–1273), Prot_S1 the complete N-terminal S1 domain (aa 1–692) and Prot_S
+
parts of the C-terminal S2 domain (aa 689–895).

Applications

PepTivator
®
SARS-CoV-2 Prot_S Complete – research grade has been specifically developed for in vitro stimulation of SARS-CoV-2– specific T cells. Peptides of 15 amino acids in length and 11 amino acids overlap represent an optimized solution for stimulating both CD4
+
and CD8
+
T cells in various applications, including:
  • Detection and analysis of SARS-CoV-2–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies
  • Isolation of viable SARS-CoV-2–specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines
  • Generation of SARS-CoV-2–specific CD4+ and CD8+ effector/ memory T cells from naive T cell populations
  • Pulsing of antigen-presenting cells, e.g. for research on dendritic cell vaccination
More information regarding the work with antigen-specific T cells can be found in the T cell application section.

References for
PepTivator
®
SARS-CoV-2 Prot_S Complete

Publications

  1. Hall, V. G. et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipient Am. J. Transplant. (doi: 10.1111/ajt.16766)
  2. Thieme, C. J. et al. (2020) Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Rep Med. 1(6): 100092

Related products for
PepTivator
®
SARS-CoV-2 Prot_S Complete

12 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?